Skip to content
value.today

Trellis Bioscience Inc.

Total raised
$49 M
5 rounds on record
Latest round
$9 M
Jan 2026
First round on record
Jul 2009
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Trellis Bioscience Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2026$9 MNo. 5$2 to $10 million

Trellis Bioscience Inc.: Raise no. 5, Jan 2026

Investors in this round

16 investors had bought by the notice of Oct 29, 2026: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, other: Series C Interests
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Larry Kauvar · Executive Officer · Chief Science Officer
  • Nora Mende · Executive Officer · Chief Financial Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nora Mende, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 29, 2026. Read the notice at the SEC.

equitySEC
Oct 2024$4 MNo. 4$2 to $10 million

Trellis Bioscience Inc.: Raise no. 4, Oct 2024

Investors in this round

27 investors had bought by the notice of Oct 21, 2026: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Series 2024 Bridge. Includes convertible notes with 20% warrant coverage.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Larry Kauvar · Executive Officer · Chief Science Officer
  • Nora Mende · Executive Officer · Chief Financial Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nora Mende, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 21, 2026. Read the notice at the SEC.

equity, optionsSEC
Apr 2023$1 MNo. 3Under $2 million

Trellis Bioscience Inc.: Raise no. 3, Apr 2023

Investors in this round

9 investors had bought by the notice of Oct 21, 2026: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Series 2023 Bridge. Includes convertible notes with 20% warrant coverage.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Larry Kauvar · Executive Officer · Chief Science Officer
  • Nora Mende · Executive Officer · Chief Financial Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nora Mende, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 21, 2026. Read the notice at the SEC.

equity, optionsSEC
Apr 2010$23 MNo. 2$10 to $50 million

Trellis Bioscience Inc.: Raise no. 2, Apr 2010

Investors in this round

88 investors had bought by the notice of Oct 21, 2026: 88 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Series B Interests
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Larry Kauvar · Executive Officer · Chief Science Officer
  • Nora Mende · Executive Officer · Chief Financial Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nora Mende, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 21, 2026. Read the notice at the SEC.

equity, optionsSEC
Jul 2009$12 MNo. 1$10 to $50 million

Trellis Bioscience Inc.: Raise no. 1, Jul 2009

Investors in this round

12 investors had bought by the notice of Aug 7, 2009: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $14 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Lawrence M. Kauvar · Executive Officer, Director
  • Stote Ellsworth · Executive Officer, Director
  • Gerald McMahon · Director
  • James Broderick · Director
  • John Friedman · Director
  • Markus Goebel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stote Ellsworth, President. Source: SEC Form D and 1 amendment, newest notice filed Aug 7, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Trellis Bioscience Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2026).

    SEC Form D · Oct 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2026

That is all the official record says: Trellis Bioscience Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Trellis Bioscience Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 88 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Trellis Bioscience Inc.
NameRoleNamed in
Elisabeth WhitneyChief Operating OfficerMay 2026
Geoff DillonChief Business OfficerMay 2026
Larry KauvarChief Science OfficerMay 2026
Nora MendeChief Financial OfficerMay 2026
Stefan RyserPresident and Chief Executive OfficerMay 2026
Lawrence M. KauvarExecutive officerAug 2009
Stote EllsworthExecutive officerAug 2009
Gerald McMahonDirectorAug 2009
James BroderickDirectorAug 2009
John FriedmanDirectorAug 2009
Lawrence M. KauvarDirectorAug 2009
Markus GoebelDirectorAug 2009
Stote EllsworthDirectorAug 2009